Spinocerebellar Degenerations Clinical Trial
Official title:
The Efficacy of High-Dose Intravenous Immunoglobulin Therapy In Patients With Cerebellar Degeneration: A Double Blind, Placebo Controlled Trial
This study will examine whether high-dose intravenous immunoglobulin (IVIG) is safe and
effective for treating cerebellar ataxia-degeneration of the cerebellum, the part of the
brain responsible for coordinating muscle movements and balance. The disease causes a slowly
progressive impairment of speech and balance, with patients often developing slurred speech,
tremor, clumsiness of the hands, and walking difficulties (ataxia). IVIG is derived from
donated blood that has been purified, cleaned and processed into a form that can be infused.
IVIG is an immune suppressant that is routinely used to treat other neurological conditions.
Patients 18 years of age and older with hereditary (genetic) or sporadic (unknown cause)
cerebellar degeneration may be eligible for this 5-month study. They must have evidence of
an immune component to their condition, such as gluten sensitivity or antiganglioside
antibodies. Candidates will be screened with a neurological examination, a review of medical
records and possibly blood tests.
Participants will be randomly assigned to receive infusions of either IVIG or placebo (an
inactive substance) through an arm vein once a month for two months. The infusions will be
given in the hospital in doses divided over 2 days, each lasting 6 to 10 hours. Before the
infusions, patients will undergo ataxia assessments through tests of coordination and
balance that may involve finger tapping, walking in a straight line, talking, and eye
movements. When the treatment is finished, patients will be followed in the clinic once a
month for 3 months for blood tests repeat ataxia assessments to evaluate the effects of
treatment.
There is increasing evidence that there is an antibody mediated, autoimmune component in hereditary and sporadic cerebellar degeneration. The objective of this study is to show clinical improvement or stabilization in ataxia using treatment with intravenous immunoglobulin (IVIG) treatment. This study is a clinical, randomized, placebo-controlled trial of IVIG in adult patients with cerebellar ataxia. Patients will be selected from the motor control clinic based on a diagnosis of sporadic or hereditary cerebellar degeneration. Study drug (placebo versus active) will be given in an intravenous infusion over a 2-day period while the patient is hospitalized. This will be repeated monthly for 2 months. Efficacy measurement will include clinical ataxia rating scales, motor speed testing and clinical gait evaluation. These will be performed at baseline, during each hospitalization, and 1 month following final IVIG infusion. Main outcome measure will be difference from baseline in score on the NINDS ataxia rating scale 1 month following 2 treatments of 2 mg/kg IVIG (total 4 mg/kg). ;
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04750850 -
Core Stability Exercises and Hereditary Ataxia
|
N/A | |
| Active, not recruiting |
NCT06152133 -
Telerehabilitation, Core Stability Exercises and Hereditary Ataxia (TRCore-ataxia)
|
N/A | |
| Completed |
NCT03120013 -
Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia
|
N/A |